See more : Mariner Corporation Limited (MCX.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Chengdu Kanghong Pharmaceutical Group Co., Ltd (002773.SZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Chengdu Kanghong Pharmaceutical Group Co., Ltd, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Alpine Immune Sciences, Inc. (ALPN) Income Statement Analysis – Financial Results
- Sesoda Corporation (1708.TW) Income Statement Analysis – Financial Results
- NatureCell Co.,Ltd. (007390.KQ) Income Statement Analysis – Financial Results
- Unite and Grow Inc. (4486.T) Income Statement Analysis – Financial Results
- Fujimori Kogyo Co., Ltd. (7917.T) Income Statement Analysis – Financial Results
Chengdu Kanghong Pharmaceutical Group Co., Ltd (002773.SZ)
About Chengdu Kanghong Pharmaceutical Group Co., Ltd
Chengdu Kanghong Pharmaceuticals Group Co., Ltd engages in the research, development, production, and sale of biological products, Chinese medicines, and chemical drugs in China. It offers ophthalmic systems, central nervous systems, digestive systems, and other system drugs. The company was founded in 1996 and is headquartered in Chengdu, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.96B | 3.39B | 3.61B | 3.30B | 3.26B | 2.92B | 2.79B | 2.54B | 2.07B | 1.67B | 1.48B | 1.33B | 1.02B | 796.09M | 638.21M |
| Cost of Revenue | 438.84M | 388.04M | 354.61M | 329.74M | 263.85M | 228.51M | 269.29M | 243.62M | 225.50M | 193.49M | 171.31M | 156.98M | 114.95M | 84.02M | 67.40M |
| Gross Profit | 3.52B | 3.00B | 3.25B | 2.97B | 2.99B | 2.69B | 2.52B | 2.30B | 1.85B | 1.48B | 1.31B | 1.17B | 901.58M | 712.07M | 570.81M |
| Gross Profit Ratio | 88.91% | 88.55% | 90.16% | 89.99% | 91.90% | 92.17% | 90.34% | 90.41% | 89.13% | 88.45% | 88.40% | 88.21% | 88.69% | 89.45% | 89.44% |
| Research & Development | 421.68M | 374.00M | 1.01B | 1.68B | 286.94M | 230.37M | 191.93M | 122.23M | 99.39M | 75.50M | 59.57M | 47.02M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 166.44M | 149.24M | 162.10M | 290.03M | 212.60M | 229.77M | 192.51M | 178.97M | 125.26M | 120.96M | 130.73M | 124.12M | 192.60M | 169.41M | 153.92M |
| Selling & Marketing | 843.30M | 1.32B | 1.40B | 1.41B | 1.57B | 1.38B | 1.28B | 1.35B | 1.10B | 870.95M | 713.09M | 651.33M | 486.37M | 389.00M | 298.28M |
| SG&A | 1.94B | 1.47B | 1.57B | 1.70B | 1.78B | 1.61B | 1.47B | 1.52B | 1.22B | 991.91M | 843.83M | 775.45M | 678.97M | 558.41M | 452.20M |
| Other Expenses | -107.42M | 221.26M | 168.97M | 166.94M | 157.51M | 3.25M | -24.47M | 16.72M | 21.63M | 9.83M | 19.86M | 32.84M | 27.53M | 13.90M | 182.00K |
| Operating Expenses | 2.26B | 2.06B | 2.74B | 3.54B | 2.22B | 1.96B | 1.76B | 1.78B | 1.44B | 1.17B | 1.01B | 916.21M | 695.98M | 570.82M | 462.18M |
| Cost & Expenses | 2.70B | 2.45B | 3.10B | 3.87B | 2.49B | 2.19B | 2.03B | 2.02B | 1.66B | 1.36B | 1.18B | 1.07B | 810.93M | 654.84M | 529.57M |
| Interest Income | 52.50M | 45.08M | 35.13M | 25.88M | 32.74M | 43.62M | 34.59M | 20.30M | 9.59M | 5.10M | 4.40M | 2.61M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 150.78K | 229.44K | 915.19K | 502.13K | 572.80K | 46.04M | 30.29M | 0.00 | 127.47K | 302.61K | 1.37M | 3.67M | 2.71M | 1.56M | 0.00 |
| Depreciation & Amortization | 222.60M | 161.68M | 150.94M | 121.50M | 95.64M | 80.85M | 72.75M | 71.88M | 64.85M | 66.74M | 57.52M | 49.37M | 30.70M | 26.96M | 22.38M |
| EBITDA | 1.39B | 1.09B | 545.90M | -396.43M | 932.09M | 881.57M | 836.22M | 640.02M | 528.46M | 407.83M | 384.27M | 342.10M | 236.30M | 168.20M | 131.02M |
| EBITDA Ratio | 35.09% | 32.41% | 20.97% | -12.18% | 26.53% | 27.60% | 30.89% | 25.12% | 25.32% | 24.36% | 29.26% | 23.07% | 23.51% | 21.79% | 20.75% |
| Operating Income | 1.26B | 1.02B | 606.69M | -574.09M | 820.75M | 796.20M | 787.53M | 556.74M | 437.82M | 329.56M | 352.87M | 219.13M | 178.32M | 123.76M | 103.99M |
| Operating Income Ratio | 31.87% | 29.96% | 16.83% | -17.42% | 25.20% | 27.29% | 28.26% | 21.92% | 21.11% | 19.68% | 23.90% | 16.46% | 17.54% | 15.55% | 16.29% |
| Total Other Income/Expenses | -27.15M | 14.93M | 38.24M | -7.22M | 14.43M | 3.25M | -24.47M | 16.53M | 18.57M | 8.06M | 19.55M | -7.32M | 27.07M | 13.56M | -155.90K |
| Income Before Tax | 1.23B | 1.03B | 393.42M | -519.51M | 835.18M | 799.46M | 763.06M | 567.75M | 456.38M | 337.62M | 372.43M | 250.87M | 205.38M | 137.32M | 103.83M |
| Income Before Tax Ratio | 31.18% | 30.40% | 10.91% | -15.76% | 25.64% | 27.40% | 27.38% | 22.35% | 22.00% | 20.16% | 25.22% | 18.84% | 20.20% | 17.25% | 16.27% |
| Income Tax Expense | 202.79M | 164.49M | -27.66M | -249.66M | 116.99M | 104.51M | 118.86M | 67.63M | 59.40M | 61.15M | 53.29M | 45.09M | 37.72M | 28.81M | 21.39M |
| Net Income | 1.04B | 896.67M | 421.08M | -269.85M | 718.19M | 694.94M | 644.20M | 496.75M | 393.81M | 273.48M | 315.71M | 202.75M | 165.03M | 108.51M | 82.45M |
| Net Income Ratio | 26.40% | 26.46% | 11.68% | -8.19% | 22.05% | 23.82% | 23.12% | 19.56% | 18.98% | 16.33% | 21.38% | 15.23% | 16.23% | 13.63% | 12.92% |
| EPS | 1.14 | 0.98 | 0.46 | -0.29 | 0.82 | 0.80 | 0.74 | 0.57 | 0.48 | 0.35 | 0.40 | 0.26 | 0.22 | 0.17 | 0.13 |
| EPS Diluted | 1.14 | 0.98 | 0.46 | -0.29 | 0.82 | 0.80 | 0.73 | 0.57 | 0.48 | 0.35 | 0.40 | 0.26 | 0.22 | 0.17 | 0.13 |
| Weighted Avg Shares Out | 916.46M | 919.46M | 919.46M | 919.46M | 873.50M | 868.68M | 872.35M | 872.67M | 824.39M | 780.00M | 779.35M | 775.32M | 748.38M | 641.18M | 643.09M |
| Weighted Avg Shares Out (Dil) | 916.46M | 919.46M | 919.46M | 919.46M | 873.50M | 868.68M | 881.54M | 872.67M | 824.41M | 780.00M | 779.98M | 779.94M | 748.38M | 641.18M | 643.09M |
No news found for: 002773.SZ
Source: https://incomestatements.info
Category: Stock Reports